SOST

Summary

Gene Symbol: SOST
Description: sclerostin
Alias: CDD, DAND6, SOST1, VBCH, sclerostin
Species: human
Products:     SOST

Top Publications

  1. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico R, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010;95:2248-53 pubmed publisher
    b>Sclerostin, a Wnt signaling antagonist on the osteoblasts produced by osteocytes, is regulated by mechanical strain and is implicated in the pathogenesis of disuse bone loss. There are no data on sclerostin in humans...
  2. Amrein K, Amrein S, Drexler C, Dimai H, Dobnig H, Pfeifer K, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012;97:148-54 pubmed publisher
    b>Sclerostin is produced by osteocytes and inhibits bone formation through the Wnt/?-catenin-signaling pathway. Only limited data are available on circulating sclerostin levels in healthy subjects...
  3. Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis P. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29:921-5 pubmed
    ..activator of nuclear factor-kappaB ligand (RANKL), Wnt signalling pathway inhibitors Dickkopf-1 (Dkk-1) and sclerostin, markers of bone resorption (C-terminal cross-linking telopeptide of collagen type-I (CTX), tartrate-resistant ..
  4. Veverka V, Henry A, Slocombe P, Ventom A, Mulloy B, Muskett F, et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem. 2009;284:10890-900 pubmed publisher
    The secreted glycoprotein sclerostin has recently emerged as a key negative regulator of Wnt signaling in bone and has stimulated considerable interest as a potential target for therapeutics designed to treat conditions associated with ..
  5. Ardawi M, Rouzi A, Al Sibiani S, Al Senani N, Qari M, Mousa S. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res. 2012;27:2592-602 pubmed publisher
    b>Sclerostin regulates bone formation by inhibiting Wnt pathway signaling. Low circulating sclerostin levels cause high bone mass...
  6. Arasu A, Cawthon P, Lui L, Do T, Arora P, Cauley J, et al. Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab. 2012;97:2027-32 pubmed publisher
    b>Sclerostin, a protein secreted by osteocytes, inhibits bone formation. Individuals with genetic mutations that decrease the availability of sclerostin have very high bone mass...
  7. Gonzalez Reimers E, Martin Gonzalez C, de la Vega Prieto M, Pelazas González R, Fernandez Rodriguez C, López Prieto J, et al. Serum sclerostin in alcoholics: a pilot study. Alcohol Alcohol. 2013;48:278-82 pubmed publisher
    b>Sclerostin is an endogenous inhibitor of the Wnt/?-catenin pathway secreted by osteocytes, which inhibits osteoblast function, differentiation and survival. As a consequence, sclerostin tends to decrease bone mass...
  8. Szulc P, Boutroy S, Vilayphiou N, Schoppet M, Rauner M, Chapurlat R, et al. Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner Res. 2013;28:1760-70 pubmed publisher
    b>Sclerostin is predominantly expressed by osteocytes...
  9. Jager A, Gotz W, Lossdörfer S, Rath Deschner B. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J Periodontal Res. 2010;45:246-54 pubmed publisher
    ..Recent studies have established an important role for the secreted glycoprotein sclerostin, the product of the SOST gene, as an osteocyte-derived signal to control bone remodelling...

More Information

Publications74

  1. Ardawi M, Rouzi A, Qari M. Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab. 2012;97:3691-9 pubmed publisher
    There is limited information on the effects of mechanical loading caused by physical activity (PA) on sclerostin, IGF-I, and bone turnover markers (BTM)...
  2. Mödder U, Clowes J, Hoey K, Peterson J, McCready L, Oursler M, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011;26:27-34 pubmed publisher
    ..b>Sclerostin is an inhibitor of Wnt signaling, and circulating estrogen (E) levels are inversely associated with sclerostin ..
  3. Mirza F, Padhi I, Raisz L, Lorenzo J. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab. 2010;95:1991-7 pubmed publisher
    b>Sclerostin is a negative regulator of bone formation. The aim of the study was to compare serum sclerostin levels in premenopausal and postmenopausal women and evaluate its relationship to estrogen, TH, bone turnover, and bone mass...
  4. Krause C, Korchynskyi O, de Rooij K, Weidauer S, de Gorter D, van Bezooijen R, et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem. 2010;285:41614-26 pubmed publisher
    b>Sclerostin is expressed by osteocytes and has catabolic effects on bone. It has been shown to antagonize bone morphogenetic protein (BMP) and/or Wnt activity, although at present the underlying mechanisms are unclear...
  5. Sevetson B, Taylor S, Pan Y. Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST). J Biol Chem. 2004;279:13849-58 pubmed
    Loss-of-function mutations in the sclerosteosis gene (SOST) cause a rare sclerosing bone dysplasia characterized by skeletal overgrowth. Cbfa1/RUNX2 is a key transcriptional regulator of osteoblast function...
  6. Ten Dijke P, Krause C, de Gorter D, Lowik C, van Bezooijen R. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008;90 Suppl 1:31-5 pubmed publisher
    ..Buchem disease are rare, high-bone-mass disorders that have been linked to deficiency in the SOST gene, encoding sclerostin. Sclerostin belongs to the DAN family of glycoproteins, of which multiple family members have been shown to ..
  7. Uitterlinden A, Arp P, Paeper B, Charmley P, Proll S, Rivadeneira F, et al. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet. 2004;75:1032-45 pubmed
    ..We studied whether the sclerosteosis/van Buchem disease gene (SOST) is an osteoporosis-risk gene by examining its association with bone-mineral density (BMD)...
  8. Spatz J, Fields E, Yu E, DIVIETI PAJEVIC P, Bouxsein M, Sibonga J, et al. Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab. 2012;97:E1736-40 pubmed publisher
    ..suggest that osteocytes regulate the skeleton's response to mechanical unloading in part by an increase in sclerostin. However, few studies have reported changes in serum sclerostin in humans exposed to reduced mechanical loading...
  9. Piters E, Culha C, Moester M, van Bezooijen R, Adriaensen D, Mueller T, et al. First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function. Hum Mutat. 2010;31:E1526-43 pubmed publisher
    ..The disease is thought to be due to loss-of-function mutations in the SOST gene. The SOST gene product, sclerostin, is secreted by osteocytes and transported to the bone surface where it inhibits osteoblastic bone formation by ..
  10. Sutherland M, Geoghegan J, Yu C, Turcott E, Skonier J, Winkler D, et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone. 2004;35:828-35 pubmed
    ..The protein product of the SOST gene, sclerostin, is a bone morphogenetic protein (BMP) antagonist that decreases osteoblast activity and reduces the ..
  11. Atkins G, ROWE P, Lim H, Welldon K, Ormsby R, Wijenayaka A, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res. 2011;26:1425-36 pubmed publisher
    The identity of the cell type responsive to sclerostin, a negative regulator of bone mass, is unknown...
  12. Szulc P, Bertholon C, Borel O, Marchand F, Chapurlat R. Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res. 2013;28:855-64 pubmed publisher
    b>Sclerostin is synthesized by osteocytes and inhibits bone formation. We measured serum sclerostin levels in 710 men aged 50 years and older. Bone mineral density (BMD) was measured at the lumbar spine, hip, and distal forearm...
  13. Appel H, Ruiz Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009;60:3257-62 pubmed publisher
    Osteocytes are considered to be sensors of bone damage and regulators of bone mass by specifically expressing sclerostin, an inhibitor of bone formation...
  14. van Lierop A, Hamdy N, Hamersma H, van Bezooijen R, Power J, Loveridge N, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26:2804-11 pubmed publisher
    ..Sclerosteosis is a rare bone sclerosing dysplasia, caused by loss-of-function mutations in the SOST gene, encoding sclerostin, a negative regulator of bone formation...
  15. Choi H, Dieckmann M, Herz J, Niemeier A. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE. 2009;4:e7930 pubmed publisher
    ..b>Sclerostin is a potent osteocyte secreted inhibitor of bone formation that directly binds Lrp5 and Lrp6 and modulates both ..
  16. Cejka D, Jäger Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider D, et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant. 2012;27:226-30 pubmed publisher
    b>Sclerostin is a soluble inhibitor of osteoblast function. Sclerostin is downregulated by the parathyroid hormone (PTH)...
  17. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537-43 pubmed
    ..reducing the disease critical region to approximately 1 Mb, we used the positional cloning strategy to identify the SOST gene, which is mutated in sclerosteosis patients...
  18. Winkler D, Sutherland M, Ojala E, Turcott E, Geoghegan J, Shpektor D, et al. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem. 2005;280:2498-502 pubmed
    ..Surprisingly, sclerostin, noggin, and human BMP receptor 1A (BMPR1A)-FC fusion proteins blocked Wnt-3A-induced ALP as well as BMP-6-..
  19. Ardawi M, Al Kadi H, Rouzi A, Qari M. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011;26:2812-22 pubmed publisher
    b>Sclerostin is a secreted Wnt antagonist produced almost exclusively by osteocytes that regulates bone mass. However, there is currently limited information on the determinants of sclerostin in a large population-based study...
  20. Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab. 2013;98:3873-83 pubmed publisher
    b>Sclerostin inhibits bone formation and is involved in the bone response to mechanical loading, but the role and significance of circulating sclerostin are poorly understood...
  21. Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti M, Pulvirenti I, et al. Sclerostin levels associated with inhibition of the Wnt/?-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:3744-50 pubmed publisher
    Patients with type 2 diabetes (T2DM) have low bone turnover, poor bone quality, and circulating levels of sclerostin significantly higher than non-T2DM controls...
  22. Tu X, Rhee Y, Condon K, Bivi N, Allen M, Dwyer D, et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012;50:209-17 pubmed publisher
    b>Sclerostin, the Wnt signaling antagonist encoded by the Sost gene, is secreted by osteocytes and inhibits bone formation by osteoblasts...
  23. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280:26770-5 pubmed
    ..is characterized by overgrowth of bone tissue and is linked to mutations in the gene encoding the secreted protein SOST. Sclerosteosis shares remarkable similarities with "high bone mass" diseases caused by "gain-of-..
  24. Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser W, Goldsmith D, et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012;90:473-80 pubmed publisher
    ..the possible association of circulating concentrations of the secreted Wnt signaling inhibitors DKK1 and sclerostin with BMD and arterial stiffness in predialysis CKD...
  25. Styrkarsdottir U, Halldorsson B, Gretarsdottir S, Gudbjartsson D, Walters G, Ingvarsson T, et al. New sequence variants associated with bone mineral density. Nat Genet. 2009;41:15-7 pubmed publisher
    ..These are near the SOST gene at 17q21, the MARK3 gene at 14q32, the SP7 gene at 12q13 and the TNFRSF11A (RANK) gene at 18q21...
  26. Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286:19489-500 pubmed publisher
    Humans lacking sclerostin display progressive bone overgrowth due to increased bone formation...
  27. Thorson S, Prasad T, Sheu Y, Danielson M, Arasu A, Cummings S, et al. Sclerostin and bone strength in women in their 10th decade of life. J Bone Miner Res. 2013;28:2008-16 pubmed publisher
    b>Sclerostin is a potent inhibitor of bone formation but has been shown to correlate positively with areal bone mineral density (aBMD)...
  28. García Martín A, Rozas Moreno P, Reyes García R, Morales Santana S, García Fontana B, Garcia Salcedo J, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:234-41 pubmed publisher
    Diabetes mellitus is a risk factor for osteoporotic fractures. Sclerostin is an inhibitor of bone formation. However, there are no data about sclerostin levels in type 2 diabetes mellitus (T2DM)...
  29. Valero C, Zarrabeitia M, Hernandez J, Pineda B, Cano A, García Pérez M, et al. Relationship of sclerostin and secreted frizzled protein polymorphisms with bone mineral density: an association study with replication in postmenopausal women. Menopause. 2011;18:802-7 pubmed publisher
    Secreted frizzled-related protein and sclerostin, encoded by FRZB and SOST genes, respectively, are extracellular Wnt inhibitors that tend to decrease bone formation...
  30. Yu L, van der Valk M, Cao J, Han C, Juan T, Bass M, et al. Sclerostin expression is induced by BMPs in human Saos-2 osteosarcoma cells but not via direct effects on the sclerostin gene promoter or ECR5 element. Bone. 2011;49:1131-40 pubmed publisher
    b>Sclerostin is a secreted inhibitor of Wnt signaling and plays an essential role in the regulation of bone mass...
  31. Brunkow M, Gardner J, Van Ness J, Paeper B, Kovacevich B, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577-89 pubmed
    ..Here we report two independent mutations in a novel gene, termed "SOST." Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an ..
  32. Staehling Hampton K, Proll S, Paeper B, Zhao L, Charmley P, Brown A, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110:144-52 pubmed
    ..the coding region of any known or novel gene(s), the closest flanking genes are MEOX1 on the proximal side, and SOST on the distal side of the deletion...
  33. Delgado Calle J, Sañudo C, Bolado A, Fernandez A, Arozamena J, Pascual Carra M, et al. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes. J Bone Miner Res. 2012;27:926-37 pubmed publisher
    b>Sclerostin, encoded by the SOST gene, is a potent inhibitor of bone formation, produced by osteocytes, not by osteoblasts, but little is known about the molecular mechanisms controlling its expression...
  34. van Bezooijen R, Roelen B, Visser A, van der Wee Pals L, de Wilt E, Karperien M, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199:805-14 pubmed
    ..by high bone mass due to increased osteoblast activity, is caused by loss of the SOST gene product, sclerostin. The localization in bone and the mechanism of action of sclerostin are not yet known, but it has been ..
  35. Frings Meuthen P, Boehme G, Liphardt A, Baecker N, Heer M, Rittweger J. Sclerostin and DKK1 levels during 14 and 21 days of bed rest in healthy young men. J Musculoskelet Neuronal Interact. 2013;13:45-52 pubmed
    Wnt signaling pathway may be crucial in the pathogenesis of disuse-induced bone loss. Sclerostin and DKK1, antagonists of the Wnt signaling pathway, were assessed during immobilization by bed rest in young, healthy people...
  36. Winkler D, Sutherland M, Geoghegan J, Yu C, Hayes T, Skonier J, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22:6267-76 pubmed
    ..Sclerosteosis is a disease typified by high bone mass due to the loss of SOST expression. Sclerostin, the SOST gene protein product, competed with the type I and type II bone morphogenetic protein (BMP) receptors ..
  37. Galea G, Sunters A, Meakin L, Zaman G, Sugiyama T, Lanyon L, et al. Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4. FEBS Lett. 2011;585:2450-4 pubmed publisher
    b>Sclerostin is a potent inhibitor of bone formation which is down-regulated by mechanical loading...
  38. Huang Q, Li G, Kung A. The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. Bone. 2009;45:289-94 pubmed publisher
    ..The -9247 polymorphism rs1230399 in the upstream regulatory region of the sclerostin gene showed significant genotypic/allelic associations with spine, femoral neck, trochanter and total hip BMD (P=..
  39. Mödder U, Hoey K, Amin S, McCready L, Achenbach S, Riggs B, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26:373-9 pubmed publisher
    b>Sclerostin is a potent inhibitor of Wnt signaling and bone formation. However, there is currently no information on the relation of circulating sclerostin levels to age, gender, or bone mass in humans...
  40. Frost M, Andersen T, Gossiel F, Hansen S, Bollerslev J, Van Hul W, et al. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J Bone Miner Res. 2011;26:1721-8 pubmed publisher
    ..DXA and HR-pQCT were used to assess BMD and bone structure. Serum serotonin, sclerostin, dickkopf-related protein 1 (DKK1), and BTM were evaluated...
  41. Findlay D, Atkins G. TWEAK and TNF regulation of sclerostin: a novel pathway for the regulation of bone remodelling. Adv Exp Med Biol. 2011;691:337-48 pubmed publisher
  42. Ellies D, Viviano B, McCarthy J, Rey J, Itasaki N, Saunders S, et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 2006;21:1738-49 pubmed
    We compared and contrasted the mechanism of action for the cysteine knot protein subfamily, Wise and Sost (Sclerostin)...
  43. Poole K, van Bezooijen R, Loveridge N, Hamersma H, Papapoulos S, Löwik C, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842-4 pubmed
    ..signals have remained largely enigmatic, but it was recently reported that human osteocytes secrete sclerostin, an inhibitor of bone formation...
  44. Roudier M, Li X, Niu Q, Pacheco E, Pretorius J, Graham K, et al. Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury. Arthritis Rheum. 2013;65:721-31 pubmed publisher
    b>Sclerostin plays a major role in regulating skeletal bone mass, but its effects in articular cartilage are not known...
  45. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:91-7 pubmed
    ..In a previous study, we positionally cloned a novel gene, called SOST, from the linkage interval and identified three different, homozygous mutations in the SOST gene in sclerosteosis ..
  46. Boudin E, Yorgan T, Fijalkowski I, Sonntag S, Steenackers E, Hendrickx G, et al. The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans. J Bone Miner Res. 2017;32:1739-1749 pubmed publisher
    ..Initially, we and others reported that sclerosteosis was caused by loss-of-function mutations in SOST, encoding sclerostin. More recently, we identified disease-causing mutations in LRP4, a binding partner of sclerostin, in three ..
  47. Daniele G, Winnier D, Mari A, Bruder J, Fourcaudot M, Pengou Z, et al. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism. Diabetes Care. 2015;38:1509-17 pubmed publisher
    ..b>Sclerostin is a circulating peptide inhibiting Wnt/β-catenin signaling...
  48. Graeff C, Campbell G, Peña J, Borggrefe J, Padhi D, Kaufman A, et al. Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis. Bone. 2015;81:364-9 pubmed publisher
    Romosozumab inhibits sclerostin, thereby increasing bone formation and decreasing bone resorption...
  49. Aguirre L, Colleluori G, Dorin R, Robbins D, Chen R, Jiang B, et al. Hypogonadal Men with Higher Body Mass Index have Higher Bone Density and Better Bone Quality but Reduced Muscle Density. Calcif Tissue Int. 2017;101:602-611 pubmed publisher
    ..luteinizing hormone, follicle stimulating hormone, sex hormone-binding globulin, C-telopeptide, osteocalcin, and sclerostin were measured...
  50. Barbe M, Massicotte V, Assari S, Monroy M, Frara N, Harris M, et al. Prolonged high force high repetition pulling induces osteocyte apoptosis and trabecular bone loss in distal radius, while low force high repetition pulling induces bone anabolism. Bone. 2018;110:267-283 pubmed publisher
    ..g., microcracks, increased osteocyte apoptosis, secreted sclerostin, RANKL, and osteoclast numbers), compared to controls...
  51. Garnero P. The Utility of Biomarkers in Osteoporosis Management. Mol Diagn Ther. 2017;21:401-418 pubmed publisher
    ..Thus, novel markers such as periostin, sclerostin and, sphingosine 1-phosphate have been developed to address some of these shortcomings...
  52. Sebastian A, Hum N, Hudson B, Loots G. Cancer-Osteoblast Interaction Reduces Sost Expression in Osteoblasts and Up-Regulates lncRNA MALAT1 in Prostate Cancer. Microarrays (Basel). 2015;4:503-19 pubmed publisher
    ..with bone metabolism and cancer metastasis, including Mmp13, Il-6 and Tgfb2, and down-regulation of Wnt inhibitor Sost. To determine whether altered Sost expression in the bone microenvironment has an effect on prostate cancer ..
  53. Hofsø D, Bollerslev J, Sandbu R, Jørgensen A, Godang K, Hjelmesæth J, et al. Bone resorption following weight loss surgery is associated with treatment procedure and changes in secreted Wnt antagonists. Endocrine. 2016;53:313-21 pubmed publisher
    ..31, p < 0.01), and changes in BMI (? = -0.28, p < 0.01), dickkopf-1 (? = 0.20, p < 0.001) and sclerostin (? = 0.11, p < 0.05) were predictors of change in the bone resorption marker N-terminal telopeptide...
  54. Jeong H, Bae E, Kim H, Eun Y, Kim I, Kim H, et al. Estrogen attenuates the spondyloarthritis manifestations of the SKG arthritis model. Arthritis Res Ther. 2017;19:198 pubmed publisher
    ..Expression of TNF, interferon-?, and IL-17A was significantly reduced in E2-treated mice, whereas expression of sclerostin and Dickkopf-1 was increased in E2-treated mice compared with sham and ovariectomized mice...
  55. Nordholm A, Mace M, Gravesen E, Hofman Bang J, Morevati M, Olgaard K, et al. Klotho & Activin A in kidney injury Plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in contralateral kidney. Am J Physiol Renal Physiol. 2017;:ajprenal.00528.2017 pubmed publisher
    ..As such, increased aortic Sclerostin was observed in UUO rats compared to UNX and normal controls...
  56. Kim J, Kim A, Choi Y, Jang S, Woo G, Cha J, et al. Tumor necrosis factor-? antagonist diminishes osteocytic RANKL and sclerostin expression in diabetes rats with periodontitis. PLoS ONE. 2017;12:e0189702 pubmed publisher
    ..necrosis factor (TNF)-? stimulates the expression of receptor activator of nuclear factor-?B ligand (RANKL) and sclerostin. The objective of this study was to determine the effect of TNF-? expression of osteocytic RANKL and sclerostin ..
  57. Pirgon O, Sandal G, Cetin H, Dundar B. Low serum sclerostin levels in newborns with vitamin D deficiency. J Pediatr Endocrinol Metab. 2016;29:401-5 pubmed publisher
    b>Sclerostin is a glycoprotein produced by osteocytes that is being evaluated as a potential clinical marker of bone turnover...
  58. Morena M, Jaussent I, Dupuy A, Bargnoux A, Kuster N, Chenine L, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015;30:1345-56 pubmed publisher
    Osteoprotegerin (OPG), sclerostin and DKK1 constitute opposite bone turnover inhibitors, OPG inhibiting osteoclastogenesis while sclerostin and DKK1 exerting their inhibitory effects on osteoblastogenesis...
  59. Tsourdi E, Lademann F, Ominsky M, Rijntjes E, Köhrle J, Misof B, et al. Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism. Endocrinology. 2017;158:3765-3777 pubmed publisher
    Hyperthyroidism in mice is associated with low bone mass, high bone turnover, and high concentrations of sclerostin, a potent Wnt inhibitor...
  60. Genetos D, Toupadakis C, Raheja L, Wong A, Papanicolaou S, Fyhrie D, et al. Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts. J Cell Biochem. 2010;110:457-67 pubmed publisher
    Mutations in sclerostin function or expression cause sclerosing bone dysplasias, involving decreased antagonism of Wnt/Lrp5 signaling...
  61. Power J, Doube M, van Bezooijen R, Loveridge N, Reeve J. Osteocyte recruitment declines as the osteon fills in: interacting effects of osteocytic sclerostin and previous hip fracture on the size of cortical canals in the femoral neck. Bone. 2012;50:1107-14 pubmed publisher
    ..Osteocytes were stained with an anti-sclerostin antibody and counter-stained with toluidine blue. Adjacent sections were stained for alkaline phosphatase (ALP)...
  62. Jing D, Yan Z, Cai J, Tong S, Li X, Guo Z, et al. Low-1 level mechanical vibration improves bone microstructure, tissue mechanical properties and porous titanium implant osseointegration by promoting anabolic response in type 1 diabetic rabbits. Bone. 2018;106:11-21 pubmed publisher
    ..WBV mitigated the reductions in femoral BMP2, OCN, Wnt3a, Lrp6, and ?-catenin and inhibited Sost mRNA expression but did not alter RANKL or RANK gene expression in T1DM rabbits...
  63. Pérez Campo F, Santurtún A, García Ibarbia C, Pascual M, Valero C, Garcés C, et al. Osterix and RUNX2 are Transcriptional Regulators of Sclerostin in Human Bone. Calcif Tissue Int. 2016;99:302-9 pubmed publisher
    b>Sclerostin, encoded by the SOST gene, works as an inhibitor of the Wnt pathway and therefore is an important regulator of bone homeostasis...
  64. Wijenayaka A, Kogawa M, Lim H, Bonewald L, Findlay D, Atkins G. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE. 2011;6:e25900 pubmed publisher
    b>Sclerostin is a product of mature osteocytes embedded in mineralised bone and is a negative regulator of bone mass and osteoblast differentiation...
  65. Curtis K, Coughlin T, Mason D, Boerckel J, Niebur G. Bone marrow mechanotransduction in porcine explants alters kinase activation and enhances trabecular bone formation in the absence of osteocyte signaling. Bone. 2018;107:78-87 pubmed publisher
    ..However, sclerostin protein expression in osteocytes was not different between groups, nor was expression of osteocytic ..